drugset / Trial / NCT05114460

Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal

NCT05114460

Phase 2 Terminated 2 enrolled New York State Psychiatric Institute
RandomizedSequentialDouble-blindBasic science

Summary

The goal of the proposed, proof-of-concept study is to test the combined effects of vaporized marijuana \[Delta-9-tetrahydracannabinol (THC)\] with NLX as a proof of concept towards the possible development of a combined overdose reversal agent with improved tolerability.

Timeline

Start
2021-11-01
Primary completion
2024-10-15
Completion
2024-10-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabis Traditional medicine (herbal / TCM) 0 mg Inhaled
Subject Cannabis Traditional medicine (herbal / TCM) 12.5 mg Inhaled
Subject Cannabis Traditional medicine (herbal / TCM) 25 mg Inhaled
Subject Naloxone Small molecule 0 mg Intranasal
Subject Naloxone Small molecule 4 mg Intranasal